Literature DB >> 21464326

Differential transformation capacity of Src family kinases during the initiation of prostate cancer.

Houjian Cai1, Daniel A Smith, Sanaz Memarzadeh, Clifford A Lowell, Jonathan A Cooper, Owen N Witte.   

Abstract

Src family kinases (SFKs) are pleiotropic activators that are responsible for integrating signal transduction for multiple receptors that regulate cellular proliferation, invasion, and metastasis in a variety of human cancers. Independent groups have identified increased expression of individual SFK members during prostate cancer progression, raising the question of whether SFKs display functional equivalence. Here, we show that Src kinase, followed by Fyn kinase and then Lyn kinase, exhibit ranked tumorigenic potential during both paracrine-induced and cell-autonomous-initiated prostate cancer. This quantitative variation in transformation potential appears to be regulated in part by posttranslational palmitoylation. Our data indicate that development of inhibitors against specific SFK members could provide unique targeted therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464326      PMCID: PMC3080985          DOI: 10.1073/pnas.1103904108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  SRC: a century of science brought to the clinic.

Authors:  Alexey Aleshin; Richard S Finn
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.

Authors:  R Neil Dalton; Raj Chetty; Mary Stuart; Renee B Iacona; Alan Swaisland
Journal:  Anticancer Res       Date:  2010-07       Impact factor: 2.480

3.  Myristoylation and membrane binding regulate c-Src stability and kinase activity.

Authors:  Parag Patwardhan; Marilyn D Resh
Journal:  Mol Cell Biol       Date:  2010-06-28       Impact factor: 4.272

Review 4.  Role of Src expression and activation in human cancer.

Authors:  R B Irby; T J Yeatman
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

5.  Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.

Authors:  Michelle Giehl; Armin Leitner; Claudia Haferlach; Peter Duesberg; Wolf-Karsten Hofmann; Ralf Hofheinz; Wolfgang Seifarth; Andreas Hochhaus; Alice Fabarius
Journal:  Eur J Haematol       Date:  2010-04-16       Impact factor: 2.997

6.  Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Authors:  Kan V Lu; Shaojun Zhu; Anna Cvrljevic; Tiffany T Huang; Shawn Sarkaria; David Ahkavan; Julie Dang; Eduard B Dinca; Seema B Plaisier; Isaac Oderberg; Yohan Lee; Zugen Chen; Jeremy S Caldwell; Yongmin Xie; Joseph A Loo; David Seligson; Arnab Chakravari; Francis Y Lee; Roberto Weinmann; Timothy F Cloughesy; Stanley F Nelson; Gabriele Bergers; Thomas Graeber; Frank B Furnari; C David James; Webster K Cavenee; Terrance G Johns; Paul S Mischel
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

7.  The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.

Authors:  John DaSilva; Daniel Gioeli; Michael J Weber; Sarah J Parsons
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

8.  Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain.

Authors:  Chitose Oneyama; Takuya Iino; Kazunobu Saito; Kei Suzuki; Akira Ogawa; Masato Okada
Journal:  Mol Cell Biol       Date:  2009-10-12       Impact factor: 4.272

Review 9.  Cardiotoxicity induced by tyrosine kinase inhibitors.

Authors:  George S Orphanos; George N Ioannidis; Alexandros G Ardavanis
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

10.  Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.

Authors:  Houjian Cai; Ivan Babic; Xiao Wei; Jiaoti Huang; Owen N Witte
Journal:  Cancer Res       Date:  2010-12-06       Impact factor: 12.701

View more
  44 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.

Authors:  Yiming Wang; Christian Gratzke; Alexander Tamalunas; Beata Rutz; Anna Ciotkowska; Frank Strittmatter; Annika Herlemann; Sophie Janich; Raphaela Waidelich; Chunxiao Liu; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2016-11-01       Impact factor: 8.739

4.  CSF-1-induced Src signaling can instruct monocytic lineage choice.

Authors:  Max Endele; Dirk Loeffler; Konstantinos D Kokkaliaris; Oliver Hilsenbeck; Stavroula Skylaki; Philipp S Hoppe; Axel Schambach; E Richard Stanley; Timm Schroeder
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

5.  CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Authors:  Daniela Sicoli; Xuanmao Jiao; Xiaoming Ju; Marco Velasco-Velazquez; Adam Ertel; Sankar Addya; Zhiping Li; Sebastiano Andò; Alessandro Fatatis; Bishnuhari Paudyal; Massimo Cristofanilli; Mathew L Thakur; Michael P Lisanti; Richard G Pestell
Journal:  Cancer Res       Date:  2014-12-01       Impact factor: 12.701

Review 6.  Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis.

Authors:  Ami Patel; Harika Sabbineni; Andrea Clarke; Payaningal R Somanath
Journal:  Life Sci       Date:  2016-05-28       Impact factor: 5.037

Review 7.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

8.  Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.

Authors:  Qianjin Li; Omar Awad Alsaidan; Yongjie Ma; Sungjin Kim; Junchen Liu; Thomas Albers; Kebin Liu; Zanna Beharry; Shaying Zhao; Fen Wang; Iryna Lebedyeva; Houjian Cai
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

9.  Src, p130Cas, and Mechanotransduction in Cancer Cells.

Authors:  Hiroyuki Matsui; Ichiro Harada; Yasuhiro Sawada
Journal:  Genes Cancer       Date:  2012-05

10.  Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.

Authors:  Edwin M Posadas; Rafi S Ahmed; Theodore Karrison; Russell Z Szmulewitz; Peter H O'Donnell; James L Wade; James Shen; Murali Gururajan; Margarit Sievert; Walter M Stadler
Journal:  Prostate       Date:  2015-10-23       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.